Psychiatric manifestations of neurologic disease: Where are we headed?

Dialogues in Clinical Neuroscience

Volumn 9, Issue 2, 2007, Pages 111-124

  Lyketsos, Constantin G ^a,b,c   Kozauer, Nicholas ^b   Rabins, Peter V ^b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease, Parkinson's disease; Brain disease; Depression; Psychosis; Stroke; Traumatic brain injury

Indexed keywords

DEXTROMETHORPHAN; ETIRACETAM; LEVODOPA; QUINIDINE; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; BLOOD VESSEL INJURY; BRAIN DISEASE; BRAIN DYSFUNCTION; BRAIN INJURY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISABILITY; DISEASE ASSOCIATION; EPILEPSY; HUMAN; INCIDENCE; MEDICAL PRACTICE; MEDICAL RESEARCH; MENTAL DISEASE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; UNITED STATES;

ANIMALS; BRAIN; BRAIN DISEASES; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; NEUROSCIENCES; PSYCHIATRY; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 34447547514     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Lyketsos CG. Lessons from neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2006;18:445-449.
2. McHugh PR, Slavney PR. The Concept of Diseases. In: McHugh PR, Slavney PR. The Perspectives of Psychiatry. 2nd ed. Baltimore, MD: The Johns Hopkins University Press; 1998:45-98.
3. Jeste DV, Friedman JH. Psychiatry for Neurologists. Totowa, NJ: Humana Press; 2005.
4. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Diseases: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
5. Rao V. Psychiatric aspects of traumatic brain injury. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
6. Lyketsos CG, Rosenblatt A, Ravins PV. Forgotten frontal lobe syndrome or "Executive Dysfunction Syndrome." Psychosomatics. 2004;45:247-255.
7. Leone H, Polsnetti BW. Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? J Clin Pharm Ther. 2002;30:101-104.
8. Lee HB. Psychiatric disorders following stroke. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
9. Morris PL, Robinson RG, Andrezejewski P, Samuels J, Price TR. Association of depression with 10-year post-stroke mortality. Am J Psychiatry. 1993;150:124-129.
10. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006;11:1-7.
11. Roman GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder: a new diagnsotic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci. 2004;226:81-87.
12. Regan C, Katona C, Walker Z, et al. Relationship of vascular risk to the progression of Alzheimer's disease. Neurology. 2006;67:1326-1327.
13. Robinson RG. The Clinical Neuropsychiatry of Stroke: Cognitive, Behavioral, and Emotional Disorders Following Vascular Brain Injury. Cambridge, UK: Cambridge University Press; 1998.
14. Fedoroff JP, Lipsey JR, Starkstein SE, et al. Phenomenologic comparisons of major depression following stroke, myocardial infarction, or spinal cord lesions. J Affect Disord. 1991;22:83-89.
15. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of post-stroke mood disorders: diagnosis and outcome at one and two years. Stroke. 1987;18:837-843.
16. Morris PL, Robinson RG, Raphael B, Hopwood MJ. Lesion location and poststroke depression. J Neuropsychiatry Clin Neurosci. 1996;8:399-403.
17. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099-1104.
18. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled double-blind study. Am J Psychiatry. 2000;157:351-359.
19. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Clin Neurosci. 2005;17:447-454.
20. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughter and crying following stroke: validation of a measurement scale and a double-bind treatment study. Am J Psychiatry. 1993;150:286-293.
21. Panitch HS, Thisted RA, Smith RA, et. al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780-787.
22. Marsh L. Parkinson's disease. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
23. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol. 2005;58:773-776.
24. Marsh L, McDonald WM, Cummings J. Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Mov Disord. 2005;21:148-158.
25. Marsh L. Anxiety disorders in Parkinson's disease. Int Rev Psychiatry. 2000;12:307-318.
26. Weintraub D, Potenza MN. Impulse control disorders in Parkinson's disease. Curr Neurol Neurosci Rep. 2006;6:302-306.
27. Steinberg M. Alzheimer's disease. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
28. Steinberg M, Sheppard JME, Tschanz JT, et al. The incidence of mental and behavioral disturbances in dementia: the Cache County Study. J Neuropsychiatry Clin Neurosci. 2003;15:340-345.
29. Zubenko GS, Zubenko WN, McPherson S, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003;160:857-866.
30. Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County Study. Int J Geriatr Psychiatry. 2001;16:1043-53.
31. Olin JT, Scneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125-128.
32. Rosenberg PB, Onyike CU, Katz IR, et al. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005;20:119-127.
33. Lyketsos CG, Rabins PV, Breitner JCS. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:1037-1042.
34. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry. 2002;52:243-252.
35. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord. 2004;17:55-64.
36. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer's disease: review of the brain decade. Psychosomatics. 2003;44:388-401.
37. Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychoger. 2007 Mar 9; 1-12 [Epub ahead of print].
38. Kaplin A. Neuropsychiatric Aspects of multiple sclerosis. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
39. Mohr DQ Dick LP, Russo D, et al. The psychosocial impact of multiple sclerosis: exploring the patient's perspective. Health Psychol. 1999;18:376-382.
40. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59:674-678.
41. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193- 1196.
42. Rao SM, Leo GJ, Bemardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. Frequency, patterns, and prediction. Neurology. 1991,41:685-691.
43. Marsh L. Epilepsy. In: Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR, Eds. Psychiatric Aspects of Neurologic Disease: Practical Approaches to Patient Care. New York, NY: Oxford University Press. In press.
44. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003;54:388-398.
45. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997;170:205-228.
46. Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiractem therapy. Neurology. 2003;61:704-706.
47. Lyketsos CG, Stoline AM, Longstreet P, Lesser R, Fisher R, Folstein MF. Mania in temporal lobe epilepsy. Neuropsychiat Neuropsychol Behav Neurol. 1993;6:19-25.
48. Beard AW, Slater E. The schizophrenia-like psychosis of epilepsy. Proc R Soc Med. 1962;55:311-316.
49. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
50. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization; 1992.